Therapy News and Research

RSS

USPTO awards patent for key therapeutic ingredient in CNVN202 targeted molecular cancer therapy

Convergen LifeSciences, Inc. announced today that a United States Patent has been awarded by the U.S. Patent and Trademark Office jointly to The University of Texas System Board of Regents and The Secretary, U.S. Department of Health and Human Services.

29 Jun 2011

Mount Sinai gene therapy improves cardiac function in people with severe heart failure

Researchers at Mount Sinai School of Medicine have found in a Phase II trial that a gene therapy developed at Mount Sinai stabilized or improved cardiac function in people with severe heart failure. Patients receiving a high dose of the therapy, called SERCA2a, experienced substantial clinical benefit and significantly reduced cardiovascular hospitalizations, addressing a critical unmet need in this population.

29 Jun 2011

Gene PNPLA3 offers potential therapeutic target in chronic hepatitis C liver damage

New research confirms that a variant on the patatin-like phospholipase-3 (PNPLA3) gene increases risk of steatosis and fibrosis progression in patients with chronic hepatitis C virus (HCV). The PNPLA3 single nucleotide polymorphism (SNP) rs 738409 may represent an important genetic predictor and potential therapeutic target in chronic HCV liver damage.

29 Jun 2011

Some adult survivors of childhood cancer are at risk for multiple cancers

The largest study yet of adult childhood cancer survivors found that the first cancer is just the beginning of a lifelong battle against different forms of the disease for about 10 percent of these survivors.

29 Jun 2011

Anacor, DNDi and SCYNEXIS complete SCYX-7158 pre-clinical studies for combating sleeping sickness

Anacor Pharmaceuticals, the Drugs for Neglected Diseases initiative (DNDi), and SCYNEXIS Inc. today announced the successful completion of pre-clinical studies for the first new oral drug candidate discovered specifically to combat human African trypanosomiasis (HAT), also known as sleeping sickness.

29 Jun 2011

Prototype small molecule drugs could suppress hepatitis C

Targeted multi-drug treatments for hepatitis C patients that could stop the virus in its tracks have come a step closer, thanks to researchers at the University of Leeds, UK.

29 Jun 2011

Researchers discover herpes virus-associated disease in monkeys

Researchers at Oregon Health & Science University have discovered a naturally occurring disease in monkeys that is very much like multiple sclerosis in humans - a discovery that could have a major impact on efforts to understand the cause of multiple sclerosis.

29 Jun 2011

Bayer Yakuhin seeks marketing authorization in Japan for EYLEA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that Bayer Yakuhin, Ltd., Osaka, Japan, has submitted an application to the Ministry of Health, Labor and Welfare (MHLW) in Japan for marketing authorization for EYLEA, also known as VEGF Trap-Eye, for the treatment of the neovascular form of age-related macular degeneration (wet AMD).

29 Jun 2011

Glybera gene therapy reduces pancreatitis risk in Lipoprotein Lipase Deficiency patients

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today released data showing that its gene therapy Glybera® (alipogene tiparvovec) significantly reduces the risk of pancreatitis in patients with Lipoprotein Lipase Deficiency (LPLD). Pancreatitis, or inflammation of the pancreas, is a major clinical symptom of LPLD.

29 Jun 2011

Bristol-Myers Squibb and Mylan expand access to HIV drug Reyataz in sub-Saharan Africa and India

Bristol-Myers Squibb Company today announced a new agreement to expand access to Reyataz (atazanavir sulfate). The immunity-from-suit agreement signed with Matrix Laboratories Limited, a Mylan Company, enables the generic company to manufacture and sell atazanavir, as well as stavudine and didanosine, in sub-Saharan Africa and India.

29 Jun 2011

Genetic tools that enable cell type-specific delivery hold promise for combating incurable neurologic diseases

Novel tools and methods for delivering therapeutic genes to cells in the central nervous system hold great promise for the development of new treatments to combat incurable neurologic diseases. Five of the most exciting developments in this rapidly advancing field are presented in a series of articles in the June issue of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc..

29 Jun 2011

FDA clears Nuvo's IND for Lidocaine Spray formulation

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application filed May 27, 2011 for a novel topical Lidocaine Spray formulation (NRI-ANA), allowing for initiation of Phase 1 studies.

29 Jun 2011

Expert addresses need to improve risk stratification of heart failure patients eligible for ICD or CRT-D

Responding to a recent study showing that 40% of patients who receive CRT-ICD therapy do not benefit from the device (Sipahi, et al – 6/13/11), Wojciech Zareba, MD, PhD, stated that improving risk stratification of heart failure patients eligible for an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy with a defibrillator (CRT-D) is essential.

28 Jun 2011

Conventional Estrogen Receptor measurement methods may result in 10-20% false negative rate

A team of Yale Cancer Center researchers has confirmed that between 10-20% of breast cancers classified as Estrogen Receptor (ER) negative are really positive. Understanding when and why breast cancers may be misclassified has important implications for treatment and outcomes for women diagnosed with breast cancer. Its findings are published online in the June 28 Journal of Clinical Oncology.

28 Jun 2011

Bio-Nucleonics' generic Metastron, an option for metastatic cancer bone pain therapy

Bio-Nucleonics' lead product Strontium Chloride Sr-89 Injection USP (Strontium-89), which is the generic version of Metastron®, is an option to consider for metastatic cancer bone pain therapy, typically caused by advanced stage breast, prostate or lung cancer.

28 Jun 2011

Infection rate drops at Nebraska hospital after initiating new protocols

Nurses, occupational and physical therapists, case managers and education staff, all working together at a 300-bed Nebraska rehabilitation hospital, have successfully implemented a team approach to dramatically reduce infections from urinary catheters, the most prevalent type of infection acquired in healthcare settings.

28 Jun 2011

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

Relypsa, Inc. today announced the start of dosing in a Phase 2b clinical trial of RLY5016 for the treatment of hyperkalemia in patients with diabetic nephropathy and chronic kidney disease (CKD). RLY5016 is a high capacity, non-absorbed, polymer-based potassium binder that is orally administered and has been shown to control serum potassium levels in previous studies.

28 Jun 2011

Nine-year-old recovers with experimental heart pump

Nine-year-old Greer Underwood was healthy until February 2011. What seemingly began as sinusitis on a Tuesday became almost fatal by the weekend when her heart began to fail. Now, after a historic series of events at the University of Alabama at Birmingham, she's the only child in the country to have used the experimental heart pump, Heartware, as a bridge to transplant.

28 Jun 2011

RCSI researchers identify novel drug target for osteomyeltitis

New research from the Royal College of Surgeons in Ireland (RCSI) has identified a novel drug target for the treatment of infection in bone.

28 Jun 2011

EAS, ESC develop new European guidelines to manage dyslipidaemias

Cardiovascular disease (CVD), driven by the global pandemics of obesity and diabetes, poses a daunting challenge to clinicians in the 21st century. Despite progress, there is still much to be done to improve the control of dyslipidaemia, a key risk factor.

28 Jun 2011

Therapy News and Research

USPTO awards patent for key therapeutic ingredient in CNVN202 targeted molecular cancer therapy

Mount Sinai gene therapy improves cardiac function in people with severe heart failure

Gene PNPLA3 offers potential therapeutic target in chronic hepatitis C liver damage

Some adult survivors of childhood cancer are at risk for multiple cancers

Anacor, DNDi and SCYNEXIS complete SCYX-7158 pre-clinical studies for combating sleeping sickness

Prototype small molecule drugs could suppress hepatitis C

Researchers discover herpes virus-associated disease in monkeys

Bayer Yakuhin seeks marketing authorization in Japan for EYLEA for treatment of wet AMD

Glybera gene therapy reduces pancreatitis risk in Lipoprotein Lipase Deficiency patients

Bristol-Myers Squibb and Mylan expand access to HIV drug Reyataz in sub-Saharan Africa and India

Genetic tools that enable cell type-specific delivery hold promise for combating incurable neurologic diseases

FDA clears Nuvo's IND for Lidocaine Spray formulation

Expert addresses need to improve risk stratification of heart failure patients eligible for ICD or CRT-D

Conventional Estrogen Receptor measurement methods may result in 10-20% false negative rate

Bio-Nucleonics' generic Metastron, an option for metastatic cancer bone pain therapy

Infection rate drops at Nebraska hospital after initiating new protocols

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

Nine-year-old recovers with experimental heart pump

RCSI researchers identify novel drug target for osteomyeltitis

EAS, ESC develop new European guidelines to manage dyslipidaemias

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News